Study of injectable PNIPAAm hydrogels containing niosomal angiogenetic drug delivery system for potential cardiac tissue regeneration

• Published in: Biomedical materials (Bristol) 2021-07, Vol.16 (4), p.45031
• Main Authors: Malektaj, Haniyeh, Imani, Rana, Siadati, M Hossein
• Format: Article
• Language: English
• Subjects: Acrylic Resins - chemistry; angiogenesis; Angiogenesis Inducing Agents - chemistry; Angiogenesis Inducing Agents - pharmacokinetics; Angiogenesis Inducing Agents - pharmacology; cardiac regeneration; Cells, Cultured; Drug Delivery Systems - methods; Heart - physiology; Human Umbilical Vein Endothelial Cells; Humans; Hydrogels - chemistry; injectable hydrogel; Injections; Neovascularization, Physiologic - drug effects; niosomal rosuvastatin; PNIPAAm; Regeneration; Rosuvastatin Calcium - chemistry; Rosuvastatin Calcium - pharmacokinetics; Rosuvastatin Calcium - pharmacology; Tissue Engineering
• ISSN: 1748-6041; 1748-605X
• DOI: 10.1088/1748-605X/abdef8

Nowadays, heart disease, especially myocardial infarction, is one of the most astoundingly unfortunate causes of mortality in the world. That is why special attention has been paid toward tissue engineering techniques for curing and regeneration of heart tissue. In this study, poly( -isopropyl acrylamide) (PNIPAAm), a temperature-sensitive injectable hydrogel, was selected as a minimally invasive scaffold to accommodate, carry, and release of niosomal rosuvastatin to the inflicted area for inducing angiogenesis and thus accelerating the healing process. The characteristics of PNIPAAm were studied by scanning electron microscopy, rheology tests, and Fourier transform infrared spectroscopy. The properties of the niosomal rosuvastatin release system, including particle size distribution, zeta potential, encapsulation efficiency (EE), and drug release, were also studied. The results showed that niosomes (358 nm) had a drug EE of 78% and a loading capacity of 53%. The drug was sustainably released from the system up to about 54% in 5 d. Cellular studies showed no toxicity to the endothelial cell lines, and the niosomal drug with a concentration of 7.5 nM enhanced cell proliferation, and cell migration increased from 72% to 90% compared to the control sample. Therefore, the controlled-release of niosomal rosuvastatin enhanced angiogenesis in a dose-dependent manner. Taken together, these advantages suggest that PNIPAAm-based niosomal hydrogel provides a promising candidate as an angiogentic injectable scaffold for potential cardiac tissue regeneration.